Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07313059Recruiting

CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research

Role: lead

NCT05636514Phase 1Recruiting

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS

Role: lead

NCT07435636Phase 2Not Yet Recruiting

Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis

Role: lead

NCT06782971Recruiting

Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

Role: lead

All 4 trials loaded